Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramucirumab + docetaxel
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ramucirumab + docetaxel is a combination therapy used primarily for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after platinum-based chemotherapy. Ramucirumab is a human IgG1 monoclonal antibody that targets and antagonizes vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting angiogenesis, which is critical for tumor growth and metastasis. Docetaxel is a cytotoxic small molecule chemotherapeutic agent that promotes microtubule assembly while inhibiting their disassembly, leading to apoptosis in rapidly dividing cells. The combination has demonstrated improved survival as second-line therapy for stage IV NSCLC and may also be used in other cancers such as gastric or gastroesophageal junction adenocarcinoma.
- Brand names
- Taxotere + Cyramza
- Other names
- ramucirumab + docetaxel
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ramucirumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramucirumab + docetaxel.